G
Guillermo Alonso
Publications - 6
Citations - 610
Guillermo Alonso is an academic researcher. The author has contributed to research in topics: Lung cancer & Cisplatin. The author has an hindex of 4, co-authored 6 publications receiving 549 citations.
Papers
More filters
Journal ArticleDOI
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
Enriqueta Felip,Rafael Rosell,José Maestre,José Manuel Rodríguez-Paniagua,Teresa Moran,Julio Astudillo,Guillermo Alonso,José Manuel Borro,José Luis González-Larriba,Antoni Torres,Carlos Camps,Ricardo Guijarro,Dolores Isla,Rafael Aguiló,Vicente Alberola,José Padilla,Abel Sánchez-Palencia,Jose Javier Sanchez,Eduardo Hermosilla,Bartomeu Massuti +19 more
TL;DR: In early-stage patients, no statistically significant differences in disease-free survival were found with the addition of preoperative or adjuvant chemotherapy to surgery in this phase III trial, in which the treatment decision was made before surgery.
Journal ArticleDOI
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla,Carme Sarries,Rafael Rosell,Guillermo Alonso,Manuel Domine,Miquel Taron,Guillermo Lopez-Vivanco,Carlos Camps,M. Botia,L. Nuñez,Maria Sanchez-Ronco,Jose Javier Sanchez,Marta López-Brea,Isidoro Barneto,A. Paredes,B. Medina,Angel Artal,Pilar Lianes +17 more
TL;DR: ERCC1 SNP assessment could be an important component of tailored chemotherapy trials and patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival.
Journal ArticleDOI
The NATCH trial: Observations on the neoadjuvant arm
Enriqueta Felip,Rafael Rosell,B. Massuti,Guillermo Alonso,Jose-Luis Gonzalez-Larriba,Carlos Camps,Dolores Isla,C. Mas,José Jurado Sánchez,José Maestre +9 more
TL;DR: The neoadjuvant approach is a promising option in early-stage NSCLC since relatively low compliance rate with adjuvant therapy and incomplete recovery after surgery are commonly reported.
Journal ArticleDOI
21LBA Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. A Spanish Lung Cancer Group Trial
B. Massuti,Jose Miguel Sanchez,Guillermo Alonso,J.A. Maestre,Jose-Luis Gonzalez-Larriba,Carlos Camps,J.M. Rodriguez-Paniagua,Enriqueta Felip,J.J. Sánchez,Rafael Rosell +9 more
Journal ArticleDOI
B2-01: The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm
Enriqueta Felip,Rafael Rosell,Bartomeu Massuti,Guillermo Alonso,Jose-Luis Gonzalez-Larriba,Carlos Camps,Dolores Isla,Cristina Mas,Jose Javier Sanchez,José Maestre +9 more
TL;DR: Treatment with MGd+WBRT decreased progression in each function measured by standardized neurocognitive testing in the pooled dataset from 2 randomized phase III trials, consistent with the delay in time to clinical neurologic progression seen in a previous pooled analysis.